> LI25 Pill - white five-sided
Pill with imprint > LI25 is White, Five-sided and has been identified as Lamotrigine (Chewable, Dispersible) 25 mg. It is supplied by Cobalt Laboratories Inc.
Lamotrigine is used in the treatment of Bipolar Disorder; Lennox-Gastaut Syndrome; Epilepsy; Seizure Prevention; Seizures and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for > LI25
Lamotrigine (Chewable, Dispersible)
- Imprint
- > LI25
- Strength
- 25 mg
- Color
- White
- Shape
- Five-sided
- Availability
- Prescription only
- Drug Class
- Triazine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Cobalt Laboratories Inc
- Inactive Ingredients
-
silicon dioxide,
croscarmellose sodium,
mannitol,
magnesium stearate,
microcrystalline cellulose,
povidone k30,
magnesium silicate,
saccharin sodium
Note: Inactive ingredients may vary.
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 16252-0598 (Discontinued) | Cobalt Laboratories, Inc. |
| 68084-0335 (Discontinued) | Amerisource Health Services |
Related images for "> LI25"
More about lamotrigine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,808)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: triazine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Lamotrigine drug information
- Lamotrigine Chewable Dispersible Tablets
- Lamotrigine Extended-Release Tablets
- Lamotrigine Orally Disintegrating Tablets
Other brands
Lamictal, Lamictal XR, Subvenite, Lamictal CD, Lamictal ODT
Professional resources
- Lamotrigine monograph
- Lamotrigine (FDA)
- Lamotrigine Chewable Tablet (FDA)
- Lamotrigine Extended Release Tablet (FDA)
- Lamotrigine ODT (FDA)
- Lamotrigine Tablets (FDA)
Other brands
Lamictal, Lamictal XR, Subvenite
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.